Assessment of the efficacy and toxicity of 131I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours

@article{Nwosu2008AssessmentOT,
  title={Assessment of the efficacy and toxicity of 131I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours},
  author={Azikiwe C Nwosu and Louise A Jones and Jiten Vora and Graeme Poston and Sobhan Vinjamuri and D. Mark Pritchard},
  journal={British Journal of Cancer},
  year={2008},
  volume={98},
  pages={1053 - 1058}
}
131I-metaiodobenzylguanidine (131I-MIBG) is a licensed palliative treatment for patients with metastatic neuroendocrine tumours. We have retrospectively assessed the consequences of 131I-MIBG therapy in 48 patients (30 gastroenteropancreatic, 6 pulmonary, 12 unknown primary site) with metastatic neuroendocrine tumours attending Royal Liverpool University Hospital between 1996 and 2006. Mean age at diagnosis was 57.6 years (range 34–81). 131I-MIBG was administered on 88 occasions (mean 1.8… CONTINUE READING
14 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

I-metaiodobenzylguanidine in the management of metastatic midgut carcinoid tumors

  • MS Sywak, JL Pasieka, A McEwan, G Kline, O Rorstad
  • World J Surg 28:
  • 2004
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…